By Tom Salemi
VisionCare Ophthalmic Technologies Inc. didn't exactly crawl out of a crypt. But in the eyes of some, the Irvine,...
Visioncare's recent success in getting an FDA advisory panel to change a recommendation is a rare and noteworthy achievement. But the agency could prove to be an even more formidable barrier - and a potential catalyst for change - for the device sector going forward.
By Tom Salemi
VisionCare Ophthalmic Technologies Inc. didn't exactly crawl out of a crypt. But in the eyes of some, the Irvine,...